TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01200368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL per dose, 4 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)
Description: 0.5 mL per dose, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (7vPnC)
Description: 0.5 mL per dose, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: 0.5 mL per dose, 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: 0.5 mL per dose, 4 doses
Study: NCT06342518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT group received radial ESWT each session with a total of 2000 pulses at a frequency of 10 Hz. A gel was used at the interface, and the air pressure was set at 1.8 bar per session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ESWT
Description: The Sham-ESWT group received Sham radial ESWT each session, but without actual contact of the applicator. To enhance the illusion of treatment, gel was applied, and the device emitted sound at every shock

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resting Splint , Exercises and ice
Description: Ensuring proper usage of the wrist resting splint by the patient was confirmed during follow-up visits. The physician instructed the patients on stretching and strengthening exercises for wrist extensors, which they were asked to perform three times a day. Application of ice for 20 minutes every 3-4 hours during painful periods was recommended. During follow-up visits patients confirmed that they adherence to exercises and recommendations.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resting Splint , Exercises and ice
Description: Ensuring proper usage of the wrist resting splint by the patient was confirmed during follow-up visits. The physician instructed the patients on stretching and strengthening exercises for wrist extensors, which they were asked to perform three times a day. Application of ice for 20 minutes every 3-4 hours during painful periods was recommended. During follow-up visits patients confirmed that they adherence to exercises and recommendations.
Study: NCT03874117

Intervention type: OTHER
Group type: OTHER
Intervention: Twice weekly hemodialysis
Description: Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: Thrice weekly hemodialysis
Description: Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
Study: NCT00992355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin 0.3% - Dexamethasone 0.1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
Study: NCT02968368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03349788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LCA-nP
Description: The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LCA-P
Description: The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
Study: NCT02167516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucosamine sulfate
Description: glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule
Description: Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
Study: NCT03654937

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH \& Co. KG, Munich, Germany, batch: AFLBA 152AB.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH \& Co. KG, Munich, Germany, batch: AFLBA 152AB.
Study: NCT01460758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medial Frontal rTMS Double-Cone-Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left DLPFC Butterfly Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Stimulation
Description: Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
Study: NCT02258646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemonitoring and education/self-management
Study: NCT00694668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral treatment
Description: Brief cognitive behavioral therapy (12 sessions)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy
Description: 9 sessions MBCT in a group-format (up to 8 persons)
Study: NCT01210898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
Study: NCT00747968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byetta, Exenatide
Description: Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Byetta, Exenatide
Description: Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
Study: NCT04123496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
Study: NCT03189030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pLADD
Description: via IV infusion
Study: NCT03440671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hutox Inj
Description: Hutox Inj(Clostridium botulinum type A)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox Inj
Description: Botox Inj(Clostridium botulinum type A)
Study: NCT00945984

Intervention type: PROCEDURE
Intervention: Radical nephrectomy
Description: Surgical options to treat localized renal cell carcinoma

Intervention type: PROCEDURE
Intervention: Radical nephrectomy
Description: Surgical options to treat localized renal cell carcinoma
Study: NCT04321304

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at 2 mA
Description: Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at 4 mA
Description: Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
Study: NCT03554291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine 20 MG
Description: Famotidine 20 mg capsule taken daily for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taken daily for 24 weeks.
Study: NCT02460770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
Study: NCT00648219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan Medoxomil Tablets 40 mg
Description: 40mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benicar® Tablets 40 mg
Description: 40mg, single dose fed
Study: NCT02627599

Intervention type: DEVICE
Intervention: Breath Responsive Variable Bolus Oxygen Conserving Device
Description: Mini Electronic Oxygen Conserving Device
Study: NCT04110483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer
Description: After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of non-muscle-invasive bladder cancer
Description: After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
Study: NCT00480779

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GLB Group
Description: The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GLB DVD
Description: The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
Study: NCT04043312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim SuperRapid
Description: Transcutaneous magnetic stimulation targeting the left stellate ganglion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim SuperRapid
Description: Sham transcutaneous magnetic stimulation.
Study: NCT00876304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04802540
Description: Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules every 12 hours for 10 days
Study: NCT03829371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous Injection
Study: NCT02445027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH OCT Imaging Capsule
Description: Imaging of the esophagus using the OCT Capsule and system.
Study: NCT01172652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive control
Study: NCT00005669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCL
Description: Medication studied for ability to alter body weight and body composition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control capsules for metformin
Study: NCT00613509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2) Melanoma multi-antigen therapeutic vaccine
Description: 0.5 mL, 2 cycles

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intron A, Interferon alpha -2b
Description: 0.5 mL, 5 times per week for 4 weeks
Study: NCT02166983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted cognitive training
Description: Complete Lumosity cognitive exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted cognitive training
Description: Complete Lumosity cognitive exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive intervention
Description: Complete Active Journaling cognitive exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mind-body intervention procedure
Description: Complete relaxation exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mind-body intervention procedure
Description: Complete relaxation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory intervention
Description: Complete compensatory strategies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory intervention
Description: Complete compensatory strategies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00560690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg oral three times a day for 6 months
Study: NCT00560690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: 180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
Study: NCT04135872

Intervention type: OTHER
Intervention: strengthened nuitritional treatment
Description: improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
Study: NCT04167150

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)
Description: Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)
Description: Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
Study: NCT02400658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IORT with CT-Guided HDR Brachytherapy
Description: This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
Study: NCT04459936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: URICORI
Description: Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
Study: NCT04069650

Intervention type: PROCEDURE
Intervention: Free flap
Description: Free flap reconstruction of the oral cavity
Study: NCT00560690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pegylated interferon
Description: 180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
Study: NCT01334502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: IV
Study: NCT01061398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac CT Angiography
Description: Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)
Description: Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
Study: NCT02078557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892
Study: NCT00836407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pancreatic Cancer Vaccine
Description: The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.